菜单
Telephone sharing button Contact Us linkedin sharing button LinkedIn wechat sharing button YouTube wechat sharing button Twitter mailbox sharing button info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button

Press Releases

WuXi Biologics Receives AAA MSCI ESG Rating for Second Consecutive Year
Nov. 07, 2024
WuXi Biologics Receives AAA MSCI ESG Rating for Second Consecutive Year

Shanghai, November 7, 2024 – WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has received an AAA rating from Morgan Stanley Capital International (MSCI) ESG Ratings. This marks the second consecutive year the company has been recognized with the highest rating for its outstanding performance in the key areas of Product Safety and Quality, Human Capital Development, Corporate Governance and Corporate Behavior, and Climate Change.

 

MSCI is a leading provider of critical support tools and services for the global investment community. The purpose of its annual ESG Ratings is to measure a company’s resilience to long-term ESG risks. Companies are rated on an industry-relative scale – from AAA (Leaders) to CCC (Laggards) – across the most relevant key issues, according to their exposure to ESG risks and how well they manage those risks relative to peers. Earlier this year, WuXi Biologics was also named to multiple ESG & Climate Change Indexes including the MSCI 2024 ESG Leaders Indexes for its outstanding sustainability performance.

 

Dr. Chris Chen, WuXi Biologics CEO and Chairman of the ESG Committee, commented, “We are proud to once again achieve the highest rating from MSCI, a significant acknowledgement of our ESG accomplishments. This renewed AAA rating is a testament to the effective implementation of our ESG approaches and our unwavering commitment to sustainability – in alignment with the company’s vision and mission. Moving forward, it will serve as an additional impetus for us to persist in our sustainability efforts, pushing the boundaries and demonstrating our leadership in the biologics CRDMO industry for a healthier and greener future.”

 

In line with the United Nations Sustainable Development Goals, WuXi Biologics has been making significant progress in pursuing sustainable development and socially responsible policy initiatives. To demonstrate its commitment, the company is a participant in the United Nations Global Compact, as well as the global Science Based Targets initiative (SBTi).

 

The company’s efforts have been recognized by major ESG rating agencies. It has been awarded the distinguished Platinum Medal by EcoVadis; incorporated into the DJSI World Index and Emerging Markets Index; acclaimed as an Industry and Regional Top-Rated Company by Sustainalytics; featured in the CDP Water Security “A list” and awarded an “A-” CDP Climate Change score; selected as a Constituent of the FTSE4Good Index Series; and included in the Hang Seng ESG 50 Index.

 

 

About WuXi Biologics

 

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

 

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2024, WuXi Biologics is supporting 742 integrated client projects, including 16 in commercial manufacturing (excluding COVID CMO and non-COVID dormant CMO projects).

 

WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.

 

For more information about WuXi Biologics, please visit: www.wuxibiologics.com

 

Contacts

 

ESG

esg@wuxibiologics.com

 

Media

PR@wuxibiologics.com